CD19L-sTRAIL fusion protein, human

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
012320062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVE To investigate the inhibitory effect of MenSC-sTRAIL on the apoptosis of A549 cells of lung cancer in a nude mouse… (More)
Is this relevant?
2017
2017
The recombinant sTRAIL has been in clinical trial for various human malignancies. However, the half-life time of sTRAIL is very… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Patients with B cell precursor acute lymphoblastic leukemia (BPL) respond well to chemotherapy at initial diagnosis; however… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2015
2015
Mesenchymal stem cells (MSCs) are believed to be a potential vehicle delivering antitumor agents for their tumor-homing capacity… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2013
2013
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively kill tumor cells and enhance therapy in vivo… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Mesenchymal stem cells (MSCs) are an attractive candidate for cell-based therapy. We have designed a promising double-target… (More)
Is this relevant?
2008
2008
OBJECTIVE To evaluate the impact of the recombined adeno-associated virus encoding soluble tumor necrosis factor related… (More)
Is this relevant?
2006
2006
BACKGROUND Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death in various tumor cells, but… (More)
Is this relevant?